Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOW-MCI: Ganagliflozin proline tablets in type 2 diabetes with mild cognitive impairment
ChiCTR2500111170Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ganagliflozin in type 2 diabetes mellitus (T2DM) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: MoCA Rating Scale Score. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
ganagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on ChiCTR2500111170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111170.